UTHR (United Therapeutics) Short Ratio


UTHR United Therapeutics Corp UTHR
85 GF Score
Price $554.37
GF Value $386.91
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

UTHR
85GF Score
United Therapeutics Corp UTHR
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $554.37 is trading 43.3% above its estimated GF Value™ of $386.91. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

  • Short Ratio:
  • GF Value™: $386.91 vs. price of $554.37 (43.3% above fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
85GF Score

Get the complete analysis for UTHR

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$554.37
Price
$386.91
GF Value